1. Lapatinib alters the malignant phenotype of osteosarcoma cells via downregulation of the activity of the HER2-PI3K/AKT-FASN axis in vitro
   XIN-HUA LONG et al, 2014, Oncology Reports CrossRef
2. New insights into affinity proteins for HER2-targeted therapy: Beyond trastuzumab
   Vajihe Akbari et al, 2020, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer CrossRef
3. Immunoproapoptotic molecule scFv-Fdt-tBid modified mesenchymal stem cells for prostate cancer dual-targeted therapy
   Fengqi Yan et al, 2017, Cancer Letters CrossRef
4. Recombinant immunotoxins development for HER2-based targeted cancer therapies
   Reza Mahmoudi et al, 2021, Cancer Cell International CrossRef
5. Apoptosis and apoptotic body: disease message and therapeutic target potentials
   Xuebo Xu et al, 2019, Bioscience Reports CrossRef
6. Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs
   Chenglong Chen et al, 2021, Cancer Letters CrossRef